BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17194902)

  • 1. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial.
    Ribera JM; Ortega JJ; Oriol A; Bastida P; Calvo C; Pérez-Hurtado JM; González-Valentín ME; Martín-Reina V; Molinés A; Ortega-Rivas F; Moreno MJ; Rivas C; Egurbide I; Heras I; Poderós C; Martínez-Revuelta E; Guinea JM; del Potro E; Deben G
    J Clin Oncol; 2007 Jan; 25(1):16-24. PubMed ID: 17194902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
    Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
    Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.
    Thomas X; Boiron JM; Huguet F; Dombret H; Bradstock K; Vey N; Kovacsovics T; Delannoy A; Fegueux N; Fenaux P; Stamatoullas A; Vernant JP; Tournilhac O; Buzyn A; Reman O; Charrin C; Boucheix C; Gabert J; Lhéritier V; Fiere D
    J Clin Oncol; 2004 Oct; 22(20):4075-86. PubMed ID: 15353542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
    Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
    J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
    Willemze R; Labar B
    Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
    Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
    Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
    Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients Labar B; Suciu S; Zittoun R; Muus P; Marie JP; Fillet G; Peetermans M; Stryckmans P; Willemze R; Feremans W; Jaksic B; Bourhis JH; Burghouts JP; de Witte T;
    Haematologica; 2004 Jul; 89(7):809-17. PubMed ID: 15257932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
    de Botton S; Fawaz A; Chevret S; Dombret H; Thomas X; Sanz M; Guerci A; San Miguel J; de la Serna J; Stoppa AM; Reman O; Stamatoulas A; Fey M; Cahn JY; Sotto JJ; Bourhis JH; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2005 Jan; 23(1):120-6. PubMed ID: 15534358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
    Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia.
    Willemze R; Suciu S; Mandelli F; de Witte T; Amador S;
    Ann Hematol; 2004; 83 Suppl 1():S134. PubMed ID: 15124706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience.
    Hallböök H; Hägglund H; Stockelberg D; Nilsson PG; Karlsson K; Björkholm M; Linderholm M; Wahlin A; Linder O; Smedmyr B;
    Bone Marrow Transplant; 2005 Jun; 35(12):1141-8. PubMed ID: 15834433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.
    Ribera JM; Ortega JJ; Oriol A; Fontanillas M; Hernández-Rivas JM; Brunet S; García-Conde J; Maldonado J; Zuazu J; Gardella S; Besalduch J; León P; Macià J; Domingo-Albós A; Feliu E; San Miguel JF
    Haematologica; 1998 Mar; 83(3):222-30. PubMed ID: 9573676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
    J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.
    Jourdan E; Boiron JM; Dastugue N; Vey N; Marit G; Rigal-Huguet F; Molina L; Fegueux N; Pigneux A; Recher C; Rossi JF; Attal M; Sotto JJ; Maraninchi D; Reiffers J; Bardou VJ; Esterni B; Blaise D
    J Clin Oncol; 2005 Oct; 23(30):7676-84. PubMed ID: 16186596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
    Bassan R; Rossi G; Pogliani EM; Di Bona E; Angelucci E; Cavattoni I; Lambertenghi-Deliliers G; Mannelli F; Levis A; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Borghero C; Romani C; Spinelli O; Tosi M; Oldani E; Intermesoli T; Rambaldi A
    J Clin Oncol; 2010 Aug; 28(22):3644-52. PubMed ID: 20606084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis.
    Yanada M; Matsuo K; Suzuki T; Naoe T
    Cancer; 2006 Jun; 106(12):2657-63. PubMed ID: 16703597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
    Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-intensive therapy for adult acute lymphoblastic leukemia.
    Finiewicz KJ; Larson RA
    Semin Oncol; 1999 Feb; 26(1):6-20. PubMed ID: 10073558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.